-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients' Lifespans

Sponsor: Vertex Pharmaceuticals and Chiesi USA
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies
Friday, December 8, 2023: 3:00 PM-6:00 PM
Room 6B (San Diego Convention Center)
Biree Andemariam, MD, University of Connecticut Health
Andemariam: Accordant: Consultancy; Afimmune: Consultancy; Agios: Consultancy; American Society of Hematology: Research Funding; Bluebird: Consultancy; Connecticut Department of Public Health: Research Funding; Emmaus: Consultancy; Forma Therapeutics: Consultancy, Research Funding; Global Blood Therapeutics: Consultancy, Research Funding; GSK: Consultancy; Hemanext: Consultancy, Research Funding; HRSA: Research Funding; Novartis: Consultancy, Research Funding; NovoNordisk: Consultancy; PCORI: Research Funding; Pfizer: Research Funding; Sanofi Genzyme: Consultancy; Vertex: Consultancy.
Nirmish Shah, MD, Duke University Medical Center and Lydia H Pecker, MD, Johns Hopkins University School of Medicine
Shah: Agios Pharmaceuticals: Consultancy; Global Blood Therapeutics/Pfizer: Consultancy, Research Funding, Speakers Bureau; Alexion Pharmaceuticals: Speakers Bureau; Vertex: Consultancy; Bluebird bio: Consultancy; Forma: Consultancy. Pecker: Novo Nordisk: Consultancy; Global Blood Therapeutics: Consultancy; Alexion: Research Funding.
Access Program Details

This educational activity will explore disease management approaches in SCD by focusing on
important components of successful pain management, the challenges of complications and
comorbid conditions in patients with SCD, the changing needs of patients across the lifespan
including issues pertaining to reproductive and sexual health, and the evolving treatment
landscape for patients with SCD.